What changed in September 2026
In September 2026, Precision Neuroscience closed an oversubscribed $250 million Series D round, co-led by Bill Ackman's Pershing Square, the Ackman Oxman Institute, and an undisclosed life-sciences fund, with participation from Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, and others, according to MassDevice. The round brings the company's total funding since its 2021 founding to $430 million, up from the $180 million disclosed alongside its July 2026 Donoghue advisory appointment.
MassDevice reported the proceeds will fund Precision's clinical program, further FDA review of its Layer 7 device, and commercialization infrastructure; neither the announcement nor the accompanying coverage mentioned a registration filing or an IPO timeline.
A pioneer's pioneer joins the team
On July 23, 2026, Precision Neuroscience announced that John Donoghue, Professor Emeritus at Brown University, had joined as a scientific advisor. In the early 2000s, Donoghue's lab ran the BrainGate project at Brown, and in a 2006 cover study in Nature, his team reported that a man paralyzed from the neck down could use neural signals alone to control a computer cursor, open email, and play video games -- the demonstration that established the scientific basis for the brain-computer interface industry Precision now competes in, alongside rivals such as Elon Musk's Neuralink and the Bezos- and Gates-backed Synchron.
'I've spent more than thirty years trying to get signals out of the brain and turn them into useful outputs to restore movement, control, and communication for people with paralysis,' Donoghue said in the announcement. Precision cofounder and chief science officer Benjamin Rapoport, himself a former Neuralink cofounder, called Donoghue's work the foundation for what Precision is building: 'Everything we're building at Precision extends his work -- only now, we're reading those same signals from the surface of the brain without penetrating it.'
The regulatory path, not the IPO path
Precision's Layer 7 Cortical Interface -- a microelectrode array thinner than a human hair, packing 1,024 electrodes onto a strip the company compares to a piece of scotch tape -- received FDA Breakthrough Device designation and, in April 2025, first-of-its-kind FDA authorization for temporary implantation of up to 30 days, CNBC reported at the time, allowing surgeons to use it during procedures such as brain-signal mapping. That authorization was the FDA 510(k) clearance itself, covering the temporary-use indication. By the time of the Donoghue announcement in July 2026, Precision said the array had been implanted in almost 100 patients across leading academic medical centers, up from 27 patients disclosed in December 2024.
That progression -- Breakthrough Device designation, then temporary-use authorization, then 510(k) clearance, then a stated push toward 'a long-term implant study and commercial launch' -- is a medtech regulatory pathway, not a public-markets one. None of it requires or implies an S-1.
The funding underneath the science
Founded in 2021 by CEO Michael Mager and chief science officer Benjamin Rapoport, Precision Neuroscience raised a $41 million Series B in January 2023 led by Forepont Capital Partners, then a $102 million Series C in December 2024 led by General Equity Holdings with participation from Stanley Druckenmiller's Duquesne Family Office, B Capital, and Steadview Capital -- bringing total funding to $155 million at the time, according to the company's own announcement. By its July 2026 disclosure, total funding stood at $180 million.
Mager has described the company's goal as eventually reaching a broad range of neurological conditions beyond motor paralysis, from spinal cord injury to depression, with an initial commercial focus on the roughly 315,000 Americans living with ALS, spinal cord injury, or brainstem stroke. Nothing in that roadmap, or in any funding or regulatory announcement found as of the latest site review, mentions a public listing; any specific 'Precision Neuroscience IPO date' circulating online remains speculation until the company or a filing says otherwise.